skip to main content
Visitante
Meu Espaço
Minha Conta
Sair
Identificação
This feature requires javascript
Tags
Revistas Eletrônicas (eJournals)
Livros Eletrônicos (eBooks)
Bases de Dados
Bibliotecas USP
Ajuda
Ajuda
Idioma:
Inglês
Espanhol
Português
This feature required javascript
This feature requires javascript
Primo Search
Busca Geral
Busca Geral
Acervo Físico
Acervo Físico
Produção Intelectual da USP
Produção USP
Search For:
Clear Search Box
Search in:
Busca Geral
Or hit Enter to replace search target
Or select another collection:
Search in:
Busca Geral
Busca Avançada
Busca por Índices
This feature requires javascript
This feature requires javascript
Peginterferon alfa-2a: A review of approved and investigational uses
Matthews, S.James ; McCoy, Christopher
Clinical therapeutics, 2004-07, Vol.26 (7), p.991-1025
[Periódico revisado por pares]
Belle Mead, NJ: Elsevier Inc
Texto completo disponível
Citações
Citado por
Exibir Online
Detalhes
Resenhas & Tags
Mais Opções
Nº de Citações
This feature requires javascript
Enviar para
Adicionar ao Meu Espaço
Remover do Meu Espaço
E-mail (máximo 30 registros por vez)
Imprimir
Link permanente
Referência
EasyBib
EndNote
RefWorks
del.icio.us
Exportar RIS
Exportar BibTeX
This feature requires javascript
Título:
Peginterferon alfa-2a: A review of approved and investigational uses
Autor:
Matthews, S.James
;
McCoy, Christopher
Assuntos:
Adult
;
adverse events
;
Aged
;
Animals
;
Antiviral Agents - adverse effects
;
Antiviral Agents - pharmacokinetics
;
Antiviral Agents - therapeutic use
;
Area Under Curve
;
Biological and medical
sciences
;
Child
;
Child, Preschool
;
Cost-Benefit Analysis
;
Drug Interactions
;
Female
;
Gastroenterology
;
Half-
Life
;
Hemodialysis
;
Hepatitis C
;
Hepatitis C, Chronic - drug therapy
;
Hepatology
;
Humans
;
Infections
;
Interferon
;
Interferon-alpha - adverse effects
;
Interferon-alpha - pharmacokinetics
;
Interferon-alpha - therapeutic use
;
Leukemia
;
Male
;
Medical
sciences
;
Metabolic Clearance Rate
;
Middle Aged
;
peginterferon alfa-2a
;
Pharmacokinetics
;
Pharmacology. Drug treatments
;
Polyethylene glycol
;
Polyethylene Glycols - adverse effects
;
Polyethylene Glycols - pharmacokinetics
;
Polyethylene Glycols - therapeutic use
;
Quality of
Life
;
Randomized Controlled Trials as Topic
;
Recombinant Proteins
;
therapeutic use
;
Tissue Distribution
;
Treatment Outcome
;
Viral infections
;
Viruses
É parte de:
Clinical therapeutics, 2004-07, Vol.26 (7), p.991-1025
Descrição:
Background: In October 2002, the US Food and Drug Administration approved peginterferon alfa-2a for the management of chronic hepatitis C virus (HCV) infection. The addition of polyethylene glycol (PEG) moiety to the interferon (IFN) molecule results in a product with altered pharmacokinetic properties. Objective: The aim of this article is to review the pharmacology, medications interactions, adverse events (AEs), and approved or investigational uses of PEG-IFN alfa-2a for viral hepatitis and oncologic conditions. Methods: Relevant articles were identified through searches of MEDLINE (1980–July 2003) and EMBASE (1980–July 2003). Search terms included, but were not limited to, peginterferon alfa-2a, pharmacokinetics, pharmacology, pharmacodynamics, and therapeutic use, as well as terms for specific dsease states and AEs. Further publications were identified from citations of resulting papers. Results: Pegylation of IFN alfa-2a results in major changes in the pharmacokinetics of the product. Absorption is prolonged and serum concentrations are sustained over the dosing regimen. PEG-IFN alfa-2a has been shown to be more effective with or without ribavirin (RBV), in the management of treatment-naive patients with chronic HCV infection, than unmodified IFN alfa-2a with or without RBV. Results in other disease states are still preliminary. AEs are similar, in incidence and severity, to those occurring with unmodified IFN. They include earlier hematologic symptoms and fewer influenza-like symptoms. Drug-drug interactions are the same as those occurring with the unmodified IFN product. Conclusions: The pharmacokinetic profile of IFN alfa-2a is improved by pegylation, which enables less frequent administration and results in improved efficacy with a similar side-effect profile. Combination of PEG-IFN alfa-2a with RBV is associated with a greater chance of achieving a sustained virologic response in treatment-naive patients with chronic HCV, compared with unmodified IFN alfa-2a/RBV combinations. Documentation of efficacy in other conditions awaits results of controlled clinical trials.
Editor:
Belle Mead, NJ: Elsevier Inc
Idioma:
Inglês
Links
View record in Pascal Francis
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Voltar para lista de resultados
Anterior
Resultado
9
Avançar
This feature requires javascript
This feature requires javascript
Buscando em bases de dados remotas. Favor aguardar.
Buscando por
em
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento
This feature requires javascript
This feature requires javascript